TrialJAMA oncology2026

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

Yunpeng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.